Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Psychogeriatrics ; 22(5): 631-641, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35753054

ABSTRACT

BACKGROUND: The number of dementia patients is increasing worldwide, especially in Japan, which has the world's highest ageing population. The increase in the number of older people with dementia is a medical and socioeconomic problem that needs to be prevented, but the actual situation is still not fully understood. METHODS: Four cross-sectional studies on dementia were conducted in 1997, 2004, 2012, and 2016 for complete enumeration of all residents aged 65 years and older. We examined the secular trends in the prevalence of all-cause dementia, Alzheimer's disease (AD), vascular dementia (VaD), and other/unclassified dementia. RESULTS: The age-standardised prevalence of all-cause dementia significantly increased (4.5% in 1997, 5.7% in 2004, 5.3% in 2012, 9.5% in 2016; P for trend <0.05). Similar trends were observed for AD (1.7%, 3.0%, 2.5% and 4.9%, respectively; P for trend <0.05) and other/unclassified dementia (0.8%, 1.0%, 1.0% and 2.2%, respectively; P for trend <0.05), whereas no significant change in VaD was seen (2.1%, 1.8%, 1.8%, 2.4%, respectively; P for trend = 0.77). The crude prevalence of all-cause dementia and AD increased from 1997 to 2016 among participants aged 75-79 years and ≥85 years (all P for trend <0.05). Similar trends were observed for other/unclassified dementia among participants aged ≥80 years (all P for trend <0.05), but not in VaD. CONCLUSIONS: The prevalence of dementia has increased beyond the ageing of the population, suggesting that factors in addition to ageing are involved in the increase in the number of older people with dementia. To control the increase in the number of older people with dementia, elucidation of secular trends in the incidence, mortality, and prognosis of dementia as well as the factors that promote and protect against dementia, and development of preventive strategies are necessary.


Subject(s)
Alzheimer Disease , Dementia, Vascular , Dementia , Aged , Alzheimer Disease/epidemiology , Cross-Sectional Studies , Dementia/epidemiology , Dementia, Vascular/epidemiology , Humans , Japan/epidemiology , Prevalence , Risk Factors
2.
Int J Geriatr Psychiatry ; 32(4): 407-413, 2017 04.
Article in English | MEDLINE | ID: mdl-27094214

ABSTRACT

OBJECTIVE: Impairment of visual perception frequently occurs in Alzheimer's disease (AD) and can cause severe constraints in daily activities. The nonverbal Raven's Colored Progressive Matrices (RCPM) test consists of sets A, AB, and B and is easily performed in a short time to evaluate both visual perception and reasoning ability. The purpose of this study was to evaluate the neural basis of visual perception and reasoning ability in patients with AD using RCPM and single-photon emission computed tomography (SPECT). METHODS: Fifty patients who fulfilled the National Institute on Aging/Alzheimer's Association criteria for probable AD dementia were examined with RCPM and SPECT. All SPECTs were performed using N-isopropyl-p-[123 I]-iodoamphetamine. A multiple regression model was used to perform multivariate analyses of the relationships between regional cerebral blood flow (rCBF) and RCPM scores. RESULTS: There was a significant positive correlation between RCPM total score and rCBF in the inferior parietal lobes bilaterally, the right inferior temporal gyrus, and the right middle frontal gyrus. Set A was positively correlated with rCBF in the right temporal and right parietal lobes. Set AB was positively correlated with rCBF in the right temporal, right parietal, and right frontal lobes. Set B was positively correlated with rCBF in the right parietal and right frontal lobes. CONCLUSION: Our findings suggest that deteriorations of specific brain regions are associated with dysfunction of visual perception and reasoning ability in AD. RCPM is another informative assessment scale of cognition for use in patients with AD. Copyright © 2016 John Wiley & Sons, Ltd.


Subject(s)
Alzheimer Disease/physiopathology , Brain/physiopathology , Cerebrovascular Circulation/physiology , Problem Solving/physiology , Visual Perception/physiology , Aged , Aged, 80 and over , Animals , Cognition Disorders/physiopathology , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Regression Analysis , Severity of Illness Index , Tomography, Emission-Computed, Single-Photon
3.
J Dermatol ; 43(5): 564-6, 2016 May.
Article in English | MEDLINE | ID: mdl-26507105

ABSTRACT

Bromoderma is a rare skin disorder caused by bromide intake. It presents as single or multiple papillomatous nodules or plaques, and ulcers studded with small pustules on the face or limbs. The clinical features of bromoderma are similar to those of pyoderma gangrenosum. A 41-year-old Japanese woman was diagnosed with pyoderma gangrenosum 11 years prior to presentation. Pyoderma had repeatedly appeared over her entire body despite treatment. She also frequently complained of syncopal episodes. She was admitted to our hospital after loss of consciousness and an episode of generalized convulsion. Laboratory tests revealed a negative serum anion gap and hyperchloremia. Her serum bromide level was significantly elevated, suggesting bromide intoxication. The patient had a 10-year history of high serum bromide levels. After the intake of bromide-containing sedatives was stopped, there was no recurrence of pyoderma in the absence of treatment. In conclusion, this case was diagnosed as bromoderma with commercial sedative-induced bromide intoxication. Although the US Food and Drug Administration have banned the use of bromides, over-the-counter (OTC) treatments containing bromides are still used in Japan and other countries. Long-term use of OTC medicines containing bromvalerylurea may result in the development of bromoderma. If unclarified neurological or psychiatric symptoms are associated with pyoderma, we propose measurement of the patient's serum chloride concentration. Determination of hyperchloremia is helpful for the diagnosis of chronic intoxication with bromides.


Subject(s)
Bromides/adverse effects , Bromisovalum/adverse effects , Drug Eruptions/pathology , Hypnotics and Sedatives/adverse effects , Nonprescription Drugs/adverse effects , Pyoderma Gangrenosum/pathology , Rare Diseases/pathology , Acid-Base Equilibrium , Adult , Anorexia Nervosa/drug therapy , Biopsy , Bromides/administration & dosage , Bromides/blood , Bromisovalum/blood , Bromisovalum/therapeutic use , Chlorides/blood , Cyclosporine/therapeutic use , Dermatologic Agents/therapeutic use , Drug Eruptions/blood , Drug Eruptions/etiology , Erythema/chemically induced , Erythema/drug therapy , Erythema/pathology , Female , Glucocorticoids/therapeutic use , Humans , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/therapeutic use , Nonprescription Drugs/analysis , Prednisolone/therapeutic use , Pyoderma Gangrenosum/drug therapy , Rare Diseases/blood , Rare Diseases/chemically induced , Seizures/etiology , Syncope/etiology , Withholding Treatment
4.
Int J Geriatr Psychiatry ; 30(10): 1068-75, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25694273

ABSTRACT

OBJECTIVE: This aim of this study was to examine the mechanisms underlying the neuropsychiatric symptoms in dementia with Lewy bodies by investigating regional cerebral blood flow. METHODS: Participants were 27 patients who fulfilled the diagnostic criteria for probable dementia with Lewy bodies. All subjects underwent single-photon emission computed tomography scans using technetium-99 m hexamethylpropyleneamine oxime. Neuropsychiatric symptoms were evaluated by neuropsychiatric inventory. Multiple regression analyses using neuropsychiatric inventory and voxel-based analyses of covariance of the regional cerebral blood flow images between subjects with or without each neuropsychiatric symptom were performed. Additionally, similar voxel-based analyses of covariance between subjects with each neuropsychiatric symptom and normal subjects were performed. RESULTS: There were no significant correlations in any psychiatric symptoms in multiple regression analyses. All subjects had hallucination but none had euphoria. We analyzed eight neuropsychiatric symptom scores with the exception of hallucination and euphoria using voxel-based analyses of covariance. Significant differences of regional cerebral blood flow were shown in groups with agitation, disinhibition, and irritability. Subjects with agitation showed hypoperfusion in the parietal lobule, the precuneus, and the angular gyrus, and hyperperfusion in the fusiform gyrus, the lingual gyrus, and the thalamus. Subjects with disinhibition showed hypoperfusion in the left frontal gyrus. Subjects with irritability showed hyperperfusion in the right frontal gyrus. There were no significant differences in regional cerebral blood flow between subjects with any neuropsychiatric symptoms and normal subjects. CONCLUSION: This study reveals that dysfunction of specific brain regions is associated with various neuropsychiatric symptoms in dementia with Lewy bodies.


Subject(s)
Brain/blood supply , Cerebrovascular Circulation/physiology , Lewy Body Disease/physiopathology , Aged , Aged, 80 and over , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/physiopathology , Alzheimer Disease/psychology , Female , Humans , Lewy Body Disease/diagnostic imaging , Lewy Body Disease/psychology , Male , Middle Aged , Neuropsychological Tests , Regression Analysis , Tomography, Emission-Computed, Single-Photon/methods
5.
Clin Psychopharmacol Neurosci ; 12(2): 160-2, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25191508

ABSTRACT

Clozapine is well-known for successful use in schizophrenic patients treatment resistant to other antipsychotics. However, even with clozapine, 25% of schizophrenic patients are not in remission. Recently, as adjunctive treatment with clozapine, electroconvulsive therapy has been reported to be an effective and safe adjunctive treatment. We report a Japanese schizophrenic woman who was not in remission with clozapine alone but with both clozapine and electroconvulsive therapy.

6.
Psychiatry Clin Neurosci ; 67(3): 148-53, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23581865

ABSTRACT

AIM: The purpose of this study was to compare the utility of the Rivermead Behavioural Memory Test (RBMT) and the Alzheimer's Disease Assessment Scale-Cognitive part (ADAS-Cog) for the evaluation of mild cognitive impairment (MCI) or very mild Alzheimer's disease (AD). METHODS: The discriminative abilities of RBMT and ADAS-Cog were compared in the very early stage of AD or MCI patients. Furthermore, we evaluated the difference in both RBMT score and ADAS-Cog score between different severities. RESULTS: Evident superiority in the false negative rate was observed in RBMT over ADAS-Cog in MCI or very mild AD. In addition, 86.7% of the subjects overlooked by ADAS-Cog were correctly detected by RBMT profile score. However, the RBMT score falls in the very early stages and the range of the RBMT score is rather narrow. As a result, it is difficult to evaluate status and follow the progression in severer cases. In contrast to RBMT, the ADAS-Cog score has a wide range and can evaluate and follow the severity in more severe cases. CONCLUSION: RBMT is more useful than ADAS-Cog in evaluating patients with MCI or very mild AD.


Subject(s)
Alzheimer Disease/diagnosis , Alzheimer Disease/psychology , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Memory/physiology , Neuropsychological Tests , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Psychometrics
7.
BMC Neurol ; 12: 38, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22702962

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia. Mutations in genes such as those encoding amyloid precursor protein (APP), presenilin 1 and presenilin 2, are responsible for early-onset familial AD. CASE PRESENTATION: In this study, we report a 275341 G > C (Val717Leu) mutation in the APP gene in a Japanese family with early onset AD by genetic screening. This mutation has previously been detected in European families. In the Japanese family we screened, the age at onset of AD was 47.1 ± 3.1 years old (n = 9; range, 42-52). The symptoms in the affected members included psychiatric vulnerability and focal signs such as pyramidal signs, epileptic seizures, and myoclonic discharges. An MR imaging study showed relatively mild atrophic changes in the bilateral hippocampus and cerebral cortices in all affected members compared with their clinical presentations. CONCLUSION: We conclude that the clinical features of Alzheimer's disease can be different even when caused by the same mutation in the APP gene. Further clinical and genetic studies are required to clarify the relationship between phenotypes and genotypes.


Subject(s)
Alzheimer Disease/congenital , Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Genetic Predisposition to Disease/genetics , Mutation/genetics , Pedigree , Polymorphism, Single Nucleotide/genetics , Adult , Female , Genetic Testing , Humans , Japan , Male , Middle Aged , Phenotype
8.
Psychogeriatrics ; 11(1): 46-53, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21447109

ABSTRACT

BACKGROUND: Semantic dementia (SD) has been recognized as a representative of dementia with presenile onset; however, recent epidemiological studies have shown that SD also occurs in the elderly. There have been few studies about the differences of clinical profiles between early-onset SD (EO-SD) and late-onset SD (LO-SD). Age-associated changes in the brain might cause some additional cognitive and behavioural profiles of LO-SD in contrast to the typical EO-SD cases. The aim of the present study was to clarify the characteristics of neuropsychological, and behavioural and psychological symptoms of dementia (BPSD) profiles of LO-SD patients observed in screening tests in comparison with EO-SD patients and late-onset Alzheimer's disease (LO-AD) patients as controls. METHODS: Study participants were LO-SD (n = 10), EO-SD (n = 15) and LO-AD (n = 47). We examined the Mini-Mental State Examination (MMSE), the Raven's Coloured Progressive Matrices (RCPM), the Short-Memory Questionnaire (SMQ), the Neuropsychiatric Inventory (NPI) and the Stereotypy Rating Inventory (SRI). RESULTS: Both SD groups scored significantly lower than the LO-AD patients in 'naming' of the MMSE. In the 'construction' score of the MMSE and the RCPM score, however, the LO-SD patients as well as the LO-AD patients were significantly lower than the EO-SD patients. In the SMQ score, 'euphoria' and 'disinhibition' scores of the NPI, the SRI total and subscale scores, both SD groups were significantly higher, whereas in the 'delusion' score of the NPI, both SD groups were significantly lower than the LO-AD patients. CONCLUSIONS: Visuospatial and constructive skills of LO-SD patients might be mildly deteriorated compared with EO-SD patients, whereas other cognitive and behavioural profiles of LO-SD are similar to EO-SD. Age-associated changes in the brain should be considered when we diagnose SD in elderly patients.


Subject(s)
Frontotemporal Lobar Degeneration/diagnosis , Frontotemporal Lobar Degeneration/psychology , Neuropsychological Tests , Age of Onset , Aged , Alzheimer Disease/diagnosis , Alzheimer Disease/psychology , Behavioral Symptoms , Case-Control Studies , Cognition , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Stereotyped Behavior
9.
Int Psychogeriatr ; 23(5): 772-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21205364

ABSTRACT

BACKGROUND: Memory impairment has been proposed as the most common early sign of Alzheimer's disease (AD). The aims of this work were to evaluate the risk of progression from mild memory impairment/no dementia (MMI/ND) to clinically diagnosable AD in a community-based prospective cohort and to establish the risk factors for progression from MMI/ND to AD in the elderly. METHODS: Elderly subjects aged over 65 years were selected from the participants in the first Nakayama study. MMI/ND was defined as memory deficit on objective memory assessment, without dementia, impairment of general cognitive function, or disability in activities of daily living. A total of 104 MMI/ND subjects selected from 1242 community-dwellers were followed longitudinally for five years. RESULTS: During the five-year follow-up, 11 (10.6%) subjects were diagnosed with AD, five (4.8%) with vascular dementia (VaD), and six (5.8%) with dementia of other etiology. Logistic regression analysis revealed that diabetes mellitus (DM) and a family history of dementia (within third-degree relatives) were positively associated with progression to AD, while no factor was significantly associated with progression to VaD or all types of dementia. CONCLUSIONS: DM and a family history of dementia were significant risk factors for progression from MMI/ND to clinically diagnosable AD in the elderly in a Japanese community.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Disease Progression , Mental Competency , Mental Recall , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Alzheimer Disease/etiology , Alzheimer Disease/psychology , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Executive Function , Female , Humans , Independent Living , Japan/epidemiology , Logistic Models , Male , Neuropsychological Tests , Pedigree , Prognosis , Prospective Studies , Psychiatric Status Rating Scales , Risk Factors
10.
Brain Nerve ; 62(6): 609-14, 2010 Jun.
Article in Japanese | MEDLINE | ID: mdl-20548121

ABSTRACT

AIM: The aim of this study was to use the Rivermead Behavioural Memory Test (RBMT) to evaluate everyday memory impairment among community-dwelling elderly who had normal cognitive function and performed daily activities normally but displayed memory impairments,and to diagnose the condition as either mild cognitive impairment or dementia. METHOD: Among the 1,290 community-dwelling elderly persons who participated in the study, 72 subjects scored higher than 24 on the Mini-Mental State Examination (MMSE): these subjects performed daily activities normally, but their family members reported that they showed memory impairments. Fifty-two subjects completed RBMT, Clinical Dementia Rating, and brain computed tomography, and a final diagnosis was established. RESULTS: The mean standard profile score was 15.1+/-5.0 and mean screening score was 6.4+/-3.0. RBMT score was correlated with the MMSE score. Nine of the subjects were diagnosed with dementia and 26 of them were found to be normal. RBMT achieved 100% sensitivity and specificity with regard to the differentiation of subjects with Alzheimer's disease. However, some subjects were diagnosed with dementia even though their RBMT score was higher than the cut-off score. CONCLUSION: RBMT was useful in detecting memory impairments of AD subjects in community-based surveys. However, some subjects were diagnosed with dementia because of the existence of other cognitive impairments among community-dwelling elderly.


Subject(s)
Memory Disorders/diagnosis , Neuropsychological Tests , Aged , Aged, 80 and over , Cognition Disorders/diagnosis , Dementia/diagnosis , Diagnosis, Differential , Female , Humans , Japan/epidemiology , Male , Memory Disorders/epidemiology , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...